Circle RNA Regulation of Lung Cancer Metastasis

Circle RNA对肺癌转移的调控

基本信息

  • 批准号:
    10637900
  • 负责人:
  • 金额:
    $ 32.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-04 至 2028-03-31
  • 项目状态:
    未结题

项目摘要

Lung cancer is the leading cause of cancer-related deaths in the U.S., accounting for about 132,000 deaths per year. While targeted therapies of lung adenocarcinoma have improved overall survival, similar advances in lung squamous carcinoma (LUSC) have been stagnant. Extensive molecular profiling through the Cancer Genome Atlas (TCGA) effort revealed that LUSC tumors are highly idiosyncratic and rarely driven by solitary actionable pathways. Also, metastasis, rather than primary tumors, is responsible for the majority of cancer-related deaths. However, the mechanistic underpinnings of how LUSC spreads are very poorly understood. In this proposal, we will investigate the roles of a circle RNA (circRNA), CDR1as, on its regulation of LUSC metastasis. To investigate the regulatory role of CDR1as on LUSC metastasis, we have recently developed sophisticated LUSC models that metastasize to sites common to human disease. By integrating clinical LUSC TCGA data with our mouse models, we have identified CDR1as as a key driver of LUSC metastasis. We have found that CDR1as plays a key role in stabilizing the coding mRNA transcript for cerebellar degeneration-related protein 1 (CDR1). We found that CDR1as and CDR1 are each necessary for LUSC metastasis, and CDR1 over-expression alone is sufficient to promote LUSC metastasis. We found CDR1 interacts with several specific Golgi trafficking proteins, and CDR1 expression corresponds with poor LUSC survival and tightly couples with an epithelial-mesenchymal transition (EMT) program. Additionally, we have found key structural elements of CDR1as that promote its RNA stability and expression levels. Taken together, key questions arise, such as: 1) How does CDR1 trafficking in the Golgi vesicles promote migration and metastasis? 2) Can oligo-mediated targeting of CDR1as block LUSC metastasis and prolong survival? The objectives of this proposal are to define how CDR1 promotes LUSC metastasis through Golgi trafficking. We will also determine the biologic and therapeutic implications of interrupting structural elements of CDR1as.
肺癌是美国癌症相关死亡的主要原因,每年约有13.2万人死于肺癌

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chad V Pecot其他文献

Chad V Pecot的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chad V Pecot', 18)}}的其他基金

Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
配体导向的 KRAS G12V 突变特异性治疗
  • 批准号:
    10757070
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Development of EFTX-001 to target KRAS mutations in cancer
开发 EFTX-001 以靶向癌症中的 KRAS 突变
  • 批准号:
    9906510
  • 财政年份:
    2020
  • 资助金额:
    $ 32.9万
  • 项目类别:
Immune Regulation of Lung Squamous Metastasis
肺鳞状细胞癌的免疫调节
  • 批准号:
    9770826
  • 财政年份:
    2017
  • 资助金额:
    $ 32.9万
  • 项目类别:
Immune Regulation of Lung Squamous Metastasis
肺鳞状细胞癌的免疫调节
  • 批准号:
    10237317
  • 财政年份:
    2017
  • 资助金额:
    $ 32.9万
  • 项目类别:
Immune Regulation of Lung Squamous Metastasis
肺鳞状细胞癌的免疫调节
  • 批准号:
    9445530
  • 财政年份:
    2017
  • 资助金额:
    $ 32.9万
  • 项目类别:

相似海外基金

Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
  • 批准号:
    488788
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
    Operating Grants
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
  • 批准号:
    10638347
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
  • 批准号:
    10717440
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
  • 批准号:
    10577186
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
  • 批准号:
    10749474
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
  • 批准号:
    10673458
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
  • 批准号:
    2884151
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
    Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
  • 批准号:
    10660668
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
  • 批准号:
    2239056
  • 财政年份:
    2023
  • 资助金额:
    $ 32.9万
  • 项目类别:
    Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
  • 批准号:
    468851650
  • 财政年份:
    2022
  • 资助金额:
    $ 32.9万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了